Evaluation of the Associations between Endothelial Dysfunction and Bipolar Affective Disorders: Elevated as Blood Biomarkers of Serum Endocan and Urotensin-II Level
ELIF ORAL 1*, ZEKAI HALICI 2, IRFAN CINAR 3, ELİF OZCAN 4, ZERRIN KUTLU 3
1İzmir Katip Çelebi University, Faculty of Medicine, Department of Psychiatry, 2Ataürk University, Faculty of Medicine, Department of Pharmacology, 3Atatürk University, Faculty of Pharmacy, Department of Biochemistry, 4Erzurum Regional Education and Research Hospital, Department of Psychiatry
Received: January 15, 2018; Accepted: March 2, 2018; Published online: March 2, 2018.
© The Korean College of Neuropsychopharmacology. All rights reserved.

Abstract
Objective : This study investigated changes in Urotensin-II and endocan levels which can be used as an early biological marker of endothelial injury in the episode and remission phases of Bipolar Affective Disorder (BAD).
Methods: We compared endocan and U-II levels, which has been shown to be closely associated with neurotransmitter systems in addition to continuity of endothelial structure and inflammatory response, in patients with BAD in remission for at least one year (n:42) and in patients still in manic or depressive episodes (n:16) with healthy controls (n:30).
Results: Both endocan and U-II levels were significantly higher in the bipolar patients than in the controls. Endocan and U-II levels were also significantly correlated with one another (p:0.000 and r:0,833). Both endocan (p=0.000) and U-II levels (p=0.000) were significantly higher in the bipolar attack group compared to the subjects in remission, and in the remission group compared to the controls.
Conclusion: In this study we determined significantly higher Endocan and U-II levels in BAD compared to the controls, while serum Endocan and U-II levels of patients undergoing attacks were also significantly higher than those of the controls and also those of patients in remission. Serum Endocan and U-II levels being higher in patients in the attack period compared to those in remission may indicate that endothelial and inflammatory factors underlying the disease persist despite clinical improvement.
Keywords: Endocan, Urotensin-II, Bipolar Disorder, endothelial injury


e-submission

Archives